Due to some inconsistencies in the figures provided by the first author that have come to light, and after a thorough investigation we would like to retract our paper: “Low doses of CPS49 and flavopiridol combination as potential treatment for advanced prostate cancer. By: Zalazar F, De Luca P, Gardner K, Figg WD, Meiss R, Spallanzani RG, Vallecorsa P, Elguero B,
Cotignola J, Vazquez E, De Siervi A. Curr. Pharm. Biotechnol., 2015, 16(6), 553-63.
Submission of a manuscript to the respective journals implies that all authors have read and agreed to the content of the
Copyright Letter or the Terms and Conditions. As such this article represents a severe abuse of the scientific publishing system.
Bentham Science Publishers takes a very strong view on this matter and apologizes to the readers of the journal for any
inconvenience this may cause.